Zealand Pharma A/S
CSE:ZEAL
Relative Value
The Relative Value of one ZEAL stock under the Base Case scenario is hidden DKK. Compared to the current market price of 600 DKK, Zealand Pharma A/S is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ZEAL Competitors Multiples
Zealand Pharma A/S Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
DK |
Zealand Pharma A/S
CSE:ZEAL
|
35B DKK | 102.2 | -49.8 | -62.5 | -59.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
293.9B USD | 5.4 | 49.4 | 13.8 | 21.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 5.7 | 44.5 | 18.7 | 30.9 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115B USD | 11.3 | 28.6 | 24 | 25.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.2B USD | 8.3 | 28.1 | 22.7 | 25.2 | ||
AU |
CSL Ltd
ASX:CSL
|
134.3B AUD | 6.3 | 36.4 | 22 | 27.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.4B USD | 3.1 | 174.3 | 8.8 | 11.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
50.9B USD | 9.9 | -8.5 | -9.4 | -8.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.6B USD | 3.5 | 28.8 | 14.6 | 18.3 | ||
KR |
Celltrion Inc
KRX:068270
|
39.7T KRW | 18.2 | 74.1 | 45.3 | 62.4 |